CVS Health (CVS) Q2 FY2026: Net Income Up 2.9x to $2.98B — Stock Falls 6% Despite Guidance Raise

CVS Health posted Q2 2026 revenue of $106.1 billion (+7.3%), operating income of $4.70 billion (+97.5%), and net income attributable to CVS Health of $2.98 billion (+191.8%), completing an earnings turnaround. Diluted EPS surged 2.9x from $0.80 to $2.31, while first-half net income attributable to CVS Health jumped 111.5% from $2.80 billion to $5.92 billion. The turnaround was driven by the absence of $919 million in premium deficiency reserves that weighed on the prior-year first half (Q1 2025: $448 million in individual health insurance; Q2 2025: $471 million in group Medicare Advantage), combined with a normalization of the healthcare cost ratio. On a first-half basis, the additional absence of $288 million in Accountable Care asset losses recorded only in the prior year — including a $236 million loss on the March MSSP business sale — provided a further tailwind.

Despite raising full-year guidance on the same day, CVS shares fell approximately 6% on the announcement date. The analysis below focuses on the source of that disconnect.

A note on figures: Unless otherwise indicated, "net income" throughout this report refers to net income attributable to CVS Health (Q2: $2,979 million; first half: $5,922 million). The cash flow analysis uses consolidated net income including noncontrolling interests (Q2: $2,995 million; first half: $5,952 million) and is labeled accordingly. All financial figures are sourced from the CVS Health Corporation 10-Q filed with the SEC for Q2 2026. Adjusted EPS, guidance, and share-price reaction are separately attributed to the company's Q2 2026 earnings release and related reporting dated August 5, 2026.